Tyra Biosciences (NASDAQ:TYRA) Raised to "Hold" at Wall Street Zen

Key Points

• Tyra Biosciences was upgraded from a "sell" to a "hold" rating by Wall Street Zen, while other analysts maintain a range of ratings, including one "strong buy" and one "sell".
• The stock has shown significant fluctuations in its 52-week range, with a low of $6.42 and a high of $29.60, currently trading around $13.66.
• Institutional investors own 84.14% of Tyra Biosciences shares, indicating strong institutional interest in the company as it continues to develop precision medicines for cancer treatment.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued to clients and investors on Saturday.

A number of other equities analysts also recently commented on the company. Weiss Ratings restated a "sell (d-)" rating on shares of Tyra Biosciences in a report on Saturday, September 27th. HC Wainwright reaffirmed a "buy" rating and set a $30.00 target price on shares of Tyra Biosciences in a research report on Friday, August 22nd. Raymond James Financial assumed coverage on Tyra Biosciences in a report on Tuesday, September 2nd. They set a "strong-buy" rating and a $35.00 price target on the stock. Finally, Oppenheimer reiterated an "outperform" rating and set a $36.00 price target on shares of Tyra Biosciences in a report on Wednesday, September 10th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Tyra Biosciences presently has an average rating of "Moderate Buy" and an average price target of $31.86.

Tyra Biosciences Stock Performance

NASDAQ:TYRA opened at $13.66 on Friday. The stock's 50 day moving average price is $11.92 and its 200 day moving average price is $10.47. Tyra Biosciences has a 52 week low of $6.42 and a 52 week high of $29.60. The company has a market capitalization of $728.08 million, a P/E ratio of -7.67 and a beta of 1.11.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last released its quarterly earnings data on Thursday, August 14th. The company reported ($0.47) EPS for the quarter, topping analysts' consensus estimates of ($0.53) by $0.06. As a group, sell-side analysts forecast that Tyra Biosciences will post -1.57 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of TYRA. Bank of America Corp DE lifted its position in Tyra Biosciences by 21.7% in the fourth quarter. Bank of America Corp DE now owns 66,157 shares of the company's stock worth $920,000 after purchasing an additional 11,804 shares during the period. Two Sigma Investments LP lifted its position in Tyra Biosciences by 18.1% in the fourth quarter. Two Sigma Investments LP now owns 46,269 shares of the company's stock worth $643,000 after purchasing an additional 7,093 shares during the period. Two Sigma Advisers LP bought a new position in Tyra Biosciences in the fourth quarter worth $171,000. Squarepoint Ops LLC bought a new position in shares of Tyra Biosciences during the fourth quarter valued at $253,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Tyra Biosciences by 41.4% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 35,635 shares of the company's stock valued at $495,000 after acquiring an additional 10,426 shares during the period. 84.14% of the stock is owned by institutional investors.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.